In Part 1 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how cost discipline, manufacturing shifts, and portfolio resets are reshaping large pharma.

Last week we had Eyes On more M&A counter offers + the success of M&A as Kura Oncology's Komzifti gets approved in the US (partner Kyowa Kirin). What caught you eye in BioPharma News lately?

MFN — once a policy abstraction — is now reshaping corporate strategy, pricing frameworks, and commercialization models.

The newest pharmaceutical behemoths to reach MFN pricing agreements with the White House are Eli Lilly and Novo Nordisk, who have agreed to sell their weight-loss medications to Americans at reduced costs.